Jonah Feldman

Treatment with ARV-766, an investigational proteolysis targeting chimera (PROTAC) androgen receptor degrader, led to a ≥50% PSA decline in 43% of patients with metastatic castration-resistant prostate cancer.

In a feature article incorporating Case-Based Roundtable® discussions, we look at the evolution of management for chronic graft-vs-host disease (cGVHD) following allogeneic hematopoietic cell transplantation and the impact of effective non-steroid therapies for cGVHD.

Pembrolizumab is the first agent showing overall survival benefit as adjuvant therapy in renal cell carcinoma, leading oncologists to adopt adjuvant therapy for many of their patients.

During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.

RP1 with nivolumab treatment for patients with melanoma after progression on anti–PD-1 offers durable responses and a favorable safety profile, as shown in the IGNYTE study.

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.